← Leaderboards
Harold A Harvey
Pennsylvania State Univ Hershey Med Ctr
$160,675
Attributed
$160,675
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $54.7K · FY2005–09$100K$75K$50K$25K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$160,675 · 14
By mechanism
M01$160,675 · 14
Top collaborators
No co-investigators on record.
Most similar at Pennsylvania State Univ Hershey Med Ctr
Same institution · by research overlap
- Witold B. Rybka$244,866
- Christopher Ehmann$100,551
- David F Claxton$3,137,698
- Barbara A. Miller$4,323,174
- Monika Joshi$1,466,430
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantFundingSourceResourcesResearch PersonnelUnited States National Institutes Of HealthInstitutionComputer Retrieval Of Information On Scientific Projects DatabasePaclitaxelCyclophosphamideDocetaxelClinical ResearchScheduleTaxaneTaxane CompoundToxic EffectUpper ArmTamoxifenRaloxifenePurposeIncidenceClinical TrialsWomanHuman Therapy Evaluation
Grant awards (17)
STAR$7,858
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: DOXORUBICAN-CYCLOPHOSPHAMIDE THER FOLLOW BY PACLITAXEL OR DOCETA$1,387
M01 · FY2009 · RR · contact PI
STAR$9,737
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: DOXORUBICAN-CYCLOPHOSPHAMIDE THER FOLLOW BY PACLITAXEL OR DOCETA$2,029
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: DOXORUBICAN-CYCLOPHOSPHAMIDE THER FOLLOW BY PACLITAXEL OR DOCETA$2,029
M01 · FY2008 · RR · contact PI
STAR$21,055
M01 · FY2007 · RR · contact PI
DOXORUBICAN-CYCLOPHOSPHAMIDE THER FOLLOW BY PACLITAXEL OR DOCETAXEL FOR BREAST$2,541
M01 · FY2007 · RR · contact PI
DOXORUBICAN-CYCLOPHOSPHAMIDE THER FOLLOW BY PACLITAXEL OR DOCETAXEL FOR BREAST$2,178
M01 · FY2007 · RR · contact PI
STAR$12,044
M01 · FY2006 · RR · contact PI
DOXORUBICAN-CYCLOPHOSPHAMIDE THER FOLLOW BY PACLITAXEL OR DOCETAXEL FOR BREAST$7,743
M01 · FY2006 · RR · contact PI
DOXORUBICAN-CYCLOPHOSPHAMIDE THER FOLLOW BY PACLITAXEL OR DOCETAXEL FOR BREAST$2,151
M01 · FY2006 · RR · contact PI
STAR$40,791
M01 · FY2005 · RR
DOXORUBICAN-CYCLOPHOSPHAMIDE THER FOLLOW BY PACLITAXEL OR DOCETAXEL FOR BREAST$10,878
M01 · FY2005 · RR
DOXORUBICAN-CYCLOPHOSPHAMIDE THER FOLLOW BY PACLITAXEL OR DOCETAXEL FOR BREAST$3,059
M01 · FY2005 · RR
Doxorubican-Cyclophosphamide Ther follow by Paclitaxel or Docetaxel for Breast$15,416
M01 · FY2004 · RR
STAR$12,798
M01 · FY2004 · RR
Doxorubican-Cyclophosphamide &taxanes in Breast Cancer$6,981
M01 · FY2004 · RR